Keytruda is now approved as a single agent for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥4 centimeters [cm]), II, or IIIA non-small cell lung cancer.
Affordability, supply chain constraints and access to healthcare are on everyone’s mind these days, but for people with diabetes, these are ongoing issues.